Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-Hour Application

The recruitment status of this study is unknown because the information has not been verified recently.

Verified April 2007 by Stanford University.
Recruitment status was Recruiting

Sponsor:

Information provided by:

Stanford University

ClinicalTrials.gov Identifier:

NCT00466570

First received: April 25, 2007

Last updated: April 26, 2007

Last verified: April 2007

History of Changes

Purpose

Topical ophthalmic antibiotics are common prescribed just prior to eye surgery to lower the risk of infection. Previous studies have suggested that antibiotics containing a preservative (Zymar) kill bacteria much quicker than those without a preservative (Vigamox). The purpose of this research is to compare how quickly to the two commonly prescribed antibiotics eliminate bacteria from the eye surface.

Condition	Intervention
Conjunctical Flora	Drug: gatifloxacin, moxifloxacin

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Factorial Assignment Masking: Single Blind Primary Purpose: Prevention
Official Title:	Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-Hour

Resource links provided by NLM:

MedlinePlus related topics: Antibiotics

Drug Information available for: Gatifloxacin Moxifloxacin Moxifloxacin hydrochloride

U.S. FDA Resources

Further study details as provided by Stanford University:

Primary Outcome Measures:

Antibiotic killing of conjunctival bacterial flora 1 hour after application

Estimated Enrollment:	100
Study Start Date:	April 2007

Eligibility

Ages Eligible for Study:	50 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Age- older than 50 years of age
Diagnosis- Cataract or had cataract surgery

Exclusion Criteria:

Systemic or topical antibiotic treatment within 30 days
Use of systemic or topical steroids
Active ocular infection
Ocular surgery in the past 6 months
Allergy to fluoroquinolones

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00466570

Contacts

Contact: Miri Englander, BA

650 804 8408

MiriMD@Stanford.edu

Locations

United States, California
Stanford University	Recruiting
Stanford, California, United States, 94305
Contact: Christopher Ta, MD 650-723-6995 cta@stanford.edu
Contact: Miri Englander, BA 650 804 8408
Principal Investigator: Christopher Ta, MD

Sponsors and Collaborators

Stanford University

Investigators

Principal Investigator:

Christopher Ta, MD

Stanford University

More Information

Publications:

Ta CN, He L, Nguyen E, De Kaspar HM. Prospective randomized study determining whether a 3-day application of ofloxacin results in the selection of fluoroquinolone-resistant coagulase-negative Staphylococcus. Eur J Ophthalmol. 2006 May-Jun;16(3):359-64.

Mino de Kaspar H, Koss MJ, He L, Blumenkranz MS, Ta CN. Antibiotic susceptibility of preoperative normal conjunctival bacteria. Am J Ophthalmol. 2005 Apr;139(4):730-3.

de Kaspar HM, Kreidl KO, Singh K, Ta CN. Comparison of preoperative conjunctival bacterial flora in patients undergoing glaucoma or cataract surgery. J Glaucoma. 2004 Dec;13(6):507-9.

Ta CN, Chang RT, Singh K, Egbert PR, Shriver EM, Blumenkranz MS, Mino de Kaspar H. Antibiotic resistance patterns of ocular bacterial flora: a prospective study of patients undergoing anterior segment surgery. Ophthalmology. 2003 Oct;110(10):1946-51.

Ta CN, Egbert PR, Singh K, Shriver EM, Blumenkranz MS, Mino De Kaspar H. Prospective randomized comparison of 3-day versus 1-hour preoperative ofloxacin prophylaxis for cataract surgery. Ophthalmology. 2002 Nov;109(11):2036-40; discussion 2040-1.

ClinicalTrials.gov Identifier:	NCT00466570 History of Changes
Other Study ID Numbers:	8924
Study First Received:	April 25, 2007
Last Updated:	April 26, 2007
Health Authority:	United States: Institutional Review Board

Additional relevant MeSH terms:

Gatifloxacin
Moxifloxacin
Fluoroquinolones
Norgestimate, ethinyl estradiol drug combination
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Anti-Bacterial Agents
Nucleic Acid Synthesis Inhibitors

Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Contraceptives, Oral, Combined
Contraceptives, Oral
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 23, 2013

To Top